We hope inotersen will be available to patients in the UK very soon,” he added. After a confidential price cut, Akcea has persuaded NICE to change its position on Tegsedi, paving the way for the ...
Alnylam has beaten off competition in the US from RNAi company Ionis, which is developing a rival therapy for hATTR, Tegsedi (inotersen). Inotersen has been approved in the EU, where Alnylam’s ...
It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback